Replidyne cuts jobs, stops antibiotic program

Replidyne has cut about a third of its workforce and dumped one of its development programs in a restructuring. The company announced that most of the cuts were in administration, clinical, regulatory, and commercial operations while it was suspending work on a topical antibiotic, REP8839. A late-stage trial for faropenem in acute exacerbation of chronic bronchitis is continuing. Replidyne was a 2006 Fierce 15 company.

- check out this release
- here's the AFX report on the restructuring

Related Articles:
FDA rejects Replidyne's antibiotic. Report
Replidyne files for $100M IPO. Report